Ascendis Pharma A/S vs Blackrock Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Blackrock Inc trades at $1,144.15 (market cap $177.92B). The key difference: Blackrock Inc is far larger — about 10.7× Ascendis Pharma A/S's market cap, and Blackrock Inc pays a 2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BLK | |
|---|---|---|
Market Cap | $16.67B | $177.92B |
Sector | Health | Financials |
52-Week High | $277.18 | $1.20K |
52-Week Low | $189.74 | $922.90 |
Enterprise Value | $17.04B | $179.02B |
Volume | — | 641,547 |
Dividend Yield | — | 2% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →